Histological outcome during long-term lamivudine therapy. - Wikidata - wikimedia - TriplyDB

Histological outcome during long-term lamivudine therapy.

Histological outcome during long-term lamivudine therapy.

http://www.wikidata.org/entity/Q44269261

about

Continued lamivudine for adults with lamivudine-resistant chronic hepatitis B virus infection Interferon for people with lamivudine-resistant chronic hepatitis B virus infection Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection Antiviral agents for hepatitis B virus-related cirrhosis Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapy Antiviral treatments for lamivudine-resistant chronic hepatitis B adult patients Lamivudine or adefovir dipivoxil for preventing hepatitis B recurrence after liver transplantation Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy.Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B.Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis Natural regression of fibrosis in chronic hepatitis B Clinical applications, limitations and future role of transient elastography in the management of liver disease.Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma Reversibility and heritability of liver fibrosis: Implications for research and therapy Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis.Current role of transient elastography in the management of chronic hepatitis B patients Non-invasive evaluation of liver stiffness after splenectomy in rabbits with CCl4-induced liver fibrosis Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.Current antiviral therapy for chronic hepatitis B.Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis Identification of the risk for liver fibrosis on CHB patients using an artificial neural network based on routine and serum markers.Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.Antiviral therapy and resistance with hepatitis B virus infection.A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B.Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study.Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis.Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.Barriers to screening for hepatitis B virus infection in Asian Americans.Liver cirrhosis Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.Trends in waiting list registration for liver transplantation for viral hepatitis in the United States.Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience.

P2860

Q24185958-D502EDED-9423-4C11-B184-D80D1AFD1C4F Q24185973-48D3A197-222A-4CD9-93F0-74CF1C6D979B Q24187530-E3F704A4-E5A8-4508-8FB1-6814A9AF5E11 Q24200681-2D30981B-513D-4271-9F43-BF2D1E80D4D8 Q24234212-5DD2118B-9929-4644-9268-78EF9CB5BBE1 Q24234338-A22F0555-CF9F-44BD-A30F-B881D57FB446 Q24236020-1152F4B4-E1DF-46C7-9D22-7D4990E9FAE3 Q24240881-2FF075A0-50DC-4CB1-BB55-5E53DC856597 Q24241469-C7798D04-099D-4971-8207-0D99F439FAF8 Q24244437-E08A43D5-AD6A-4623-9F61-A0A3535E719E Q24542846-1A0015D6-C155-4710-BD07-9B9149DFAE70 Q24816554-5ECB2B8A-A011-4AD8-95AC-CDE3EC36D043 Q26742104-7B8A0B5F-177B-4F3D-BA54-8F1DC499AC78 Q26746929-CE3D5D2E-7396-4142-8B32-17BDF4E311B2 Q26768262-481EB786-178F-44DE-8EBE-AEC5D18FB3DC Q26783356-B6EB789A-7939-4FC5-9A83-DBF78FA9E2F5 Q26799056-72C75916-8B32-4FB2-B33E-E476ADEBD914 Q27026622-5BEF1675-3448-49CE-A070-87B5109EE6D3 Q28088566-E10CCD3F-281F-48C9-ABD5-D98D986906B1 Q30248818-A93A0CC5-B97F-43BB-8312-322BAA9C3042 Q30358894-2A06F1B2-3C5A-411E-9828-B948FC840FDD Q30367357-DE5DAD2E-CF90-4398-9A8E-B809988B0197 Q30439873-35A7BC3A-A736-4D5D-989B-F0C7B74E3DC3 Q30443462-F9E66622-477B-4323-8C41-9AD77B1CCB41 Q33631693-B4A4983A-42D8-4B9F-AA9F-11FC0161E936 Q33652009-E23D9CE2-066A-4F70-9E66-FFCFD0E273CF Q33671532-79268DFD-CEDE-4599-926C-CF405D7D5013 Q33718935-F30DDA9E-FA6D-4BD1-858D-D99FB451FFDB Q33787531-2D2ED37F-77ED-4AF3-A187-D91AB6524729 Q33804151-A72641E1-A66C-44C1-AD1B-9E027213250A Q33855761-FABF3AF6-0607-4381-995F-4B4B845B4188 Q33868880-4617976C-FCA7-4E00-998B-38DFC0C9B2E6 Q33879651-BCAEC0D1-19D9-4E61-B537-D682FDB97844 Q33920626-31A7F3A4-A889-4390-BE34-BA848B98DB13 Q33920996-22FF3803-DC66-43D0-8611-3CC7A2ED9CF0 Q34000950-CF36A39C-B9A4-45C0-9C84-9498BDCDF462 Q34010340-36B42948-0AA2-4E7C-B1C7-B492B169E08E Q34017787-426E3A6C-952C-4B9A-80F8-E2E97341FBA3 Q34021608-EFD398A1-9D85-4BC9-830B-9808DA508B04 Q34029115-311562E8-3A86-4612-ABA4-EEB862C98050

P2860

Histological outcome during long-term lamivudine therapy.

http://www.wikidata.org/entity/Q44269261

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Histological outcome during long-term lamivudine therapy.

@en

Histological outcome during long-term lamivudine therapy.

@nl

type

label

Histological outcome during long-term lamivudine therapy.

@en

Histological outcome during long-term lamivudine therapy.

@nl

prefLabel

Histological outcome during long-term lamivudine therapy.

@en

Histological outcome during long-term lamivudine therapy.

@nl

P1433

Q44269261-06FE39DF-845A-40DF-AEC1-308FDFE312D0

P1476

Q44269261-5A9D0279-C8DD-4B30-BF56-E6D2C337B28F

P2093

Q44269261-06574711-AA44-4368-A34B-C29C35E021A0

Q44269261-16C05322-C0BE-4965-84F4-B94C42CD1D2B

Q44269261-2B7227C2-711F-4B69-B3DA-9E65E31F60E3

Q44269261-3A8E7549-1B1D-434C-932E-C50362D7207A

Q44269261-8187884F-2CCF-4E0B-B032-2875D151D672

Q44269261-9C7114BA-C090-4BF3-988A-288336F0513A

Q44269261-C1AF4D04-774A-4F68-8055-DF37C3B937AE

Q44269261-D44234F9-0785-46FE-A04A-13128318FC84

P304

Q44269261-02D294D9-4E07-48B5-AE12-D4768632A44A

P31

Q44269261-9B373CBB-A75C-4FAE-90C4-1A3F1590C06E

P356

Q44269261-FEABA300-5025-4CAC-88B3-0B5B0A3E0EDC

P407

Q44269261-08D0639D-D33A-47A6-94AF-4ABDB64950EF

P433

Q44269261-5840DC9A-69E3-4F55-80B6-536886D5775D

P478

Q44269261-6186AFA2-1525-4493-80B4-D8B37B93E509

P50

Q44269261-B25ED35C-936A-43E0-8572-8CFBB96DFAD4

P577

Q44269261-5B8FB231-C9DB-45A0-9693-719E25AE3F13

P698

Q44269261-19B9CA44-E1C7-46F6-86DE-F68EA28C2914

P356

GAST.2003.50013

P1433

Gastroenterology

P1476

Histological outcome during long-term lamivudine therapy

@en

P2093

D Fraser Gray

http://www.w3.org/2001/XMLSchema#string

E Jenny Heathcote

http://www.w3.org/2001/XMLSchema#string

Eugene R Schiff

http://www.w3.org/2001/XMLSchema#string

H W L Hann

http://www.w3.org/2001/XMLSchema#string

Mary Woessner

http://www.w3.org/2001/XMLSchema#string

Robert D Goldin

http://www.w3.org/2001/XMLSchema#string

Sally L Stephenson

http://www.w3.org/2001/XMLSchema#string

Stephen Gardner

http://www.w3.org/2001/XMLSchema#string

P304

105-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/GAST.2003.50013

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12512035

http://www.w3.org/2001/XMLSchema#string